reports
ContraFect Announces FDA Clearance of CF-370 IND Application to Procee...
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (I...
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Devel...
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. A...
ContraFect Announces Submission of IND Application to the FDA for its ...
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370 YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital...
ContraFect to Present at the World Anti-Microbial Resistance Congress ...
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023 YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from Septe...
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of ...
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of t...
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Powe...
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the presentation of data showing significant activity of its direct lytic agent...
ContraFect to Present New Data Demonstrating the Potential Efficacy of...
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023 YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Te...
ContraFect Reports First Quarter 2023 Financial Results and Provides B...
ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update YONKERS, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the first quarter ended March 31, 2023. “As a physician-scientist, I am truly excited to have begun dosing patients in our Phase 1b/2 clin...
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Ex...
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the first patient has been dosed in the Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics...
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highli...
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing CF-370 is highly efficacious in a neutropenic rabbit pneumonia model agai...
ContraFect Announces Multiple Presentations of New Data at the 33rd An...
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa New Data Elucidating the Mechanism of Action of CF-370 YONKERS, N.Y., April 06, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that t...
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in ...
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the initiation of a Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR...
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Re...
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the fourth quarter and full year ended December 31, 2022. “With the important support from our recent financings, we...
ContraFect Announces Pricing of $10.0 Million Registered Direct Offeri...
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock (or pr...
ContraFect Provides Update from the Futility Analysis of the Phase 3 D...
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase Take the Deep Dive in a Virtual Fireside Chat to be Held in Q1 2023 YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces the database lock of its Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) stu...
ContraFect Announces Pricing of $7.0 Million Registered Direct Offerin...
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $7.0 million of its common stock (or pre-...
ContraFect Announces ANSM Approval of Clinical Trial Application for E...
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that ANSM, the French National Agency for the Safety of Medicines and Health Products, has authorized its Clinical Trial Application (CTA) for the study of ...
ContraFect Reports Third Quarter 2022 Financial Results and Provides C...
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update Continued execution to advance exebacase and CF-370 into new clinical studies YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2022. “I am quite ...
ContraFect Announces Multiple Publications Highlighting the Potential ...
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the publication of an editorial in the discussing the potential for each of the Company’s lysins, exebacase and CF-296, as additi...
ContraFect Announces Presentation of New Clinical Data From a Study Us...
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the presentation by Dr. Tristan Ferry of the Infectious and Tropical Diseases Unit, Croix-Rousse ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.